Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Forest Labs., Gedeon Report Results From 2 Phase III Trials Of Cariprazine

RELATED NEWS
Trade FRX now with 

Forest Laboratories, Inc. (FRX: Quote) and Gedeon Richter Plc announced positive top-line results in 2 Phase III clinical trials of cariprazine (RGH-188) for treating acute exacerbation of schizophrenia.

For the primary endpoint in each study, the Positive And Negative Syndrome Scale, the data showed that cariprazine-treated patients experienced significant symptom improvement compared to placebo-treated patients.

Besides, all doses showed statistically significant separation from placebo starting at week 2 and at each subsequent time point with the higher dose showing separation as early as week 1 of treatment. Further analyses of the data in each study will be completed in the coming weeks.

Forest Labs noted that the results of these 2 studies were consistent with the results of the previously completed placebo-controlled Phase IIb fixed-dose study in this population.

Click here to receive FREE breaking news email alerts for Forest Laboratories Inc and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Republicans have not found much to like about President Barack Obama's nearly six years in office, but the results of a new Washington Post-ABC News poll show that a vast majority support the president's decision to launch airstrikes in Iraq. While stocks have largely maintained a positive bias over the course of the trading day on Thursday, the major averages are turning in a mixed performance in mid-day trading. The S&P 500 has reached a new record intraday high and the Dow has climbed back above 17,000, while the tech-heavy Nasdaq is posting a modest loss. Suggesting that the economy is gaining traction, the Conference Board released a report on Thursday showing a bigger than expected increase by its index of leading U.S. economic indicators in July.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.